<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294632</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0461</org_study_id>
    <secondary_id>NCI-2012-01356</secondary_id>
    <nct_id>NCT00294632</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>Lenalidomide and Rituximab Treatment of Relapsed Mantle Cell Lymphoma and Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Transformed Large Cell Lymphoma, and/or Grade 3 Follicular Lymphoma (Follicular Cleaved Large Cell Lymphoma or Follicular Non-Cleaved Large Cell Lymphoma (RV-LYM-PI-0056)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest tolerable dose of the drug
      lenalidomide (Revlimid, lenalidomide) that can be given with RituxanÂ® (rituximab) in the
      treatment of relapsed mantle cell lymphoma. The safety and effectiveness of this combination
      treatment will also be studied in both mantle cell lymphoma and diffuse large B-cell
      non-Hodgkin's lymphoma, transformed large cell lymphoma, and/or Grade 3 follicular lymphoma
      (follicular cleaved large cell lymphoma or follicular non-cleaved large cell lymphoma).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rituximab is a type of drug known as a monoclonal antibody. It is designed to act against the
      cluster of differentiation antigen 20 (CD20) antigen that is found on the surface of both
      normal B lymphocytes or on the malignant lymphoma cells. When rituximab attacks the CD20
      antigen, it can kill the lymphoma cells. lenalidomide is known as an immunomodulatory drug.
      It is thought to work by helping the immune system fight disease.

      If you are found to be eligible, you will receive lenalidomide plus rituximab. This study
      will be done in 2 phases. In the Phase I portion of this study, 6 dose levels of lenalidomide
      will be studied. The same level of rituximab will be given to all participants. Between 3-6
      participants will be treated at each dose level. Those enrolled first on this study will
      receive the lowest dose of lenalidomide plus rituximab. After treatment, each dose level of
      lenalidomide will be evaluated to check for any intolerable side effects. The dose of
      lenalidomide that you will receive will depend on the time that you enter this study and the
      side effects of those participants that entered the study before you. Once a dose has been
      assigned to you, it will not increase, but it could decrease or remain the same for a while
      if you have intolerable side effects. Once the highest tolerable dose of lenalidomide has
      been found, additional participants will receive that dose during the Phase II portion of
      this study.

      You should swallow lenalidomide capsules whole by mouth every day at the same time, with a
      glass of water on either a full or an empty stomach. Do not break, chew or open the capsules.
      This will continue for 21 days, followed by a 7-day rest period. Each 28-day period is called
      a cycle of therapy.

      If you miss a dose of lenalidomide, take it as soon as you remember on the same day. If you
      miss taking your dose for the entire day, take your regular dose the next scheduled day (do
      NOT take double your regular dose to make up for the missed dose).

      During Cycle 1 only, you will also take rituximab by vein once a week for 4 weeks (total of 4
      doses). The first rituximab infusion (by vein) usually takes 6 to 8 hours. Later infusions
      are generally shorter, taking about 4 hours to complete. For participants who have a large
      mass or who have lymphoma cells in their blood, the rituximab dose may be split into a 2-day
      infusion. Vital signs (temperature, blood pressure, respiration, and heart rate) will be
      monitored just before, during, and after the infusions. There will be an observation period
      of about 1 hour after the end of each rituximab infusion, after which you will be allowed to
      go home.

      You will be given a diary to record when you take all of the study medications and any
      problems or illnesses you experience. You should also write down in the diary any other
      medications you take while you are on this study.

      After you begin your treatment on the study drug, you will have check-up visits weekly for
      the first cycle, every 2 weeks for Cycles 2 and 3 of therapy, and then once a month for the
      rest of the study. If your doctor feels it is necessary, the check-up visits may take place
      more often. At the end of each 28-day treatment cycle, you will have a visit with the study
      doctor to see if it is safe for you to continue on this study and make sure the cancer has
      not gotten worse. If at the end of the each cycle, your doctor believes that you are eligible
      to continue (based on the degree and type of side effects you are having and the response of
      the cancer to the study drug), you will receive enough study drug for another 28-day
      treatment cycle.

      At these visits you will have a complete physical exam, including measurement of vital signs.
      You will be asked questions about how you have felt since your last visit. All medications
      you have taken since your last visit will be reviewed by the study doctor. You should bring
      the empty pill packages and any unused medication along with the diary you were given earlier
      to each visit. You will have a blood sample collected (around 8 tablespoons) for routine
      blood tests to check on the status of the disease.

      If you are eligible to continue on this study, a new 28-day supply of lenalidomide capsules
      will be given to you at this visit. Other tests may be done at these visits to check on the
      status of the disease. You may have a sample of bone marrow collected and/or have either
      x-rays or CT scans, positron emission tomography (PET) scan (if needed), and gastrointestinal
      endoscopy (for patients with known or suspected site of disease) to evaluate your response to
      therapy. These tests may not be done at every check-up visit. They will be done when your
      doctor feels they are necessary. You may have unscheduled visits at any time during this
      study if your doctor feels it is necessary for your care.

      You may continue to receive treatment as long as the cancer does not get worse and you do not
      experience any intolerable side effects. If, at any time during treatment, the disease gets
      worse or you experience any intolerable side effects, you will be taken off this study, and
      your doctor will discuss other treatment options with you. The number of weeks you are on the
      study drug depends on how well you are tolerating the study drug and how well the lymphoma
      responds to the study drugs.

      After your participation in this study ends, and if you have completed cycle 1 or more, you
      will have an end-of-study visit. At this visit you will have a complete physical exam,
      including measurement of vital signs and weight. You will have an ECG and you will be asked
      questions about how you have felt since your last visit. All medications you have taken since
      your last visit will be reviewed by the study doctor. You will have a blood sample collected
      (around 3 tablespoons) for routine blood tests to check on the status of the disease. You
      will have bone marrow collected for tests and have either x-rays or CT scans of your body to
      check on the status of the disease. You should return all empty drug packaging as well as any
      unused lenalidomide capsules at this visit.

      If you completed at least 12 and no more than 24 cycles of treatment with lenalidomide, you
      will have follow-up visits every 3 months. If you complete 24 or more cycles of treatment
      with lenalidomide, you will have follow-up visits every 6 months. This will continue until
      the disease gets worse. At each visit, blood (about 1 teaspoon) will be drawn to test your
      thyroid function. The status of your disease will be evaluated and you may have a bone marrow
      biopsy and aspirate. You will have a chest x-ray and CT scans of the chest, abdomen, and
      pelvis. If needed, you will also have a CT scan of the neck. If needed, you will have a
      colonoscopy or endoscopy. You may also have a bone marrow biopsy and aspirate performed.

      After the end-of-study visit, you will be contacted by phone every 6 months until March 15,
      2015, to check on your health and for information about any other cancer treatments you may
      have received.

      This is an investigational study. Lenalidomide is FDA approved and commercially available.
      Lenalidomide is approved for the treatment of patients with transfusion-dependent anemia due
      to Low- or Intermediate-1-risk myelodysplastic syndromes associated with the chromosome 5
      abnormality with or without other chromosome abnormalities. Lenalidomide is also approved in
      combination with dexamethasone for the treatment of patients with multiple myeloma that have
      received at least one prior therapy. Its use in this study, for relapsed mantle cell lymphoma
      or large B-cell Non-Hodgkin's lymphoma, is investigational. It is currently being tested in a
      variety of cancer conditions. In this case it is considered experimental.

      Rituximab is FDA approved and commercially available for the treatment of non-Hodgkin's
      lymphomas.

      Up to 71 participants with mantle cell lymphoma and 41 participants with diffuse large B-cell
      non-Hodgkin's lymphoma, transformed large cell lymphoma, and/or Grade 3 follicular lymphoma
      (follicular cleaved large cell lymphoma or follicular non-cleaved large cell lymphoma) will
      take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab</measure>
    <time_frame>28 days of cycle 1</time_frame>
    <description>MTD is defined as the highest dose level in which 1 or fewer participants experienced a dose limiting toxicity (DLT) in 6 participants treated. DLT is any grade III or IV toxicity during the first 28 days (first cycle) of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response of Participants Treated at Lenalidomide 20 mg</measure>
    <time_frame>56 days, assessed after 2 cycles</time_frame>
    <description>Response definitions for measurable disease from the International Workshop Standardized Response Criteria for non-Hodgkin's Lymphoma: Complete Response (CR): Disappearance of all clinical evidence of active tumor for a minimum of four weeks. Partial Response (PR): =/&gt;50% decrease in sum of products of all measured lesions persisting for &gt;four weeks. No lesion may increase in size &amp; no new lesion may appear. Minor Response (MR): &gt;25% but less than 50% response. Stable Disease: Steady state or response less than minor &amp; no progression for at least 8 weeks. There may be no appearance of significant new lesions. Progressive Disease: Unequivocal increase in size of any measurable lesion or appearance of significant new.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate of Participants Treated With Lenalidomide 20 mg: Overall Response as % of Participants With Complete or Partial Response</measure>
    <time_frame>56 days</time_frame>
    <description>Objective response rate defined as percentage of participants with complete or partial response after 2 cycles of therapy maintained for one month. Objective response monitored using Simon's optimal 2-stage design.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Starting Dose 10 mg By Mouth Daily on Days 1-21</description>
    <arm_group_label>Lenalidomide + Rituximab</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>Revlimidâ¢</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 By Vein Weekly for 4 Weeks</description>
    <arm_group_label>Lenalidomide + Rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Phase I and Phase II: Confirmed diagnosis of mantle cell lymphoma with CD20 positivity
             in tissue biopsy. Patients must have previously treated relapsed and/or refractory
             MCL. Or for Phase II: Confirmed diagnosis of previously treated relapsed and/or
             refractory diffuse large B-cell lymphoma, transformed large cell lymphoma, and/or
             Grade 3 follicular lymphoma (follicular cleaved large cell lymphoma or follicular
             non-cleaved large cell lymphoma).

          2. Understand and voluntarily sign an Institutional Review Board (IRB) approved informed
             consent form.

          3. Age equal to or greater than 18 years at the time of signing the informed consent.

          4. Patients must have bi-dimensional measurable disease (bone marrow only involvement is
             acceptable).

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.

          6. Serum bilirubin &lt;1.5 mg/dl and serum creatinine &lt; 2.0 mg/dl; platelet count
             &gt;75,000/mm^3 and absolute neutrophil count (ANC) &gt; 1,000/mm^3. AST (SGOT) and ALT
             (SGPT) &lt; 2 x upper limit of normal or &lt; 5 x upper limit of normal if hepatic
             metastases are present.

          7. Disease free of prior malignancies of equal to or greater than 5 years with exception
             of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma &quot;in
             situ&quot; of the cervix or breast, or other malignancies in remission (including prostate
             cancer patients in remission from radiation therapy, surgery or brachytherapy), not
             actively being treated, with a life expectancy &gt; 3 years.

          8. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
             test 10-14 days prior to therapy and repeated within 24 hours of starting study drug
             and must either commit to continued abstinence from heterosexual intercourse or begin
             2 acceptable methods of birth control, one highly effective method and one additional
             effective method AT THE SAME TIME, at least 4 weeks before she starts taking
             lenalidomide.

          9. Continuation from # 8 : (HIGHLY EFFECTIVE METHODS - Intrauterine device (IUD),
             hormonal (birth control pills, injections, implants), tubal ligation, partner's
             vasectomy. ADDITIONAL EFFECTIVE METHOD-latex condom, diaphragm, cervical cap) while on
             study drug.

         10. WCBP must agree to have pregnancy tests every week for the first 4 weeks of treatment,
             then every 4 weeks if her menstrual cycles are regular or every 2 weeks if her cycles
             are irregular, while on study drug, and 4 weeks after the last dose of study drug. Men
             must agree not to father a child and agree to use a condom if his partner is of child
             bearing potential.

         11. Patients may have 1 to 4 lines of prior therapy for MCL (projected median 2 prior
             lines of therapy). Patient may or may not have received an anthracycline-based
             chemotherapy regimen.

         12. Patients must be willing to receive transfusions of blood products.

         13. Past stem cell (autologous or allogenic) transplantation is acceptable.

         14. Patients may have prior therapy with rituximab.

        Exclusion Criteria:

          1. Any serious medical condition including but not limited to, uncontrolled hypertension,
             diabetes mellitus, active/symptomatic coronary artery disease, chronic obstructive
             pulmonary disease (COPD), renal failure, active infection, active hemorrhage,
             laboratory abnormality, or psychiatric illness that places the patient at unacceptable
             risk and would prevent the subject from signing the informed consent form. Patients
             with history of cardiac arrythmias should have cardiac evaluation and clearance.

          2. Pregnant or lactating females.

          3. Use of any standard/experimental anti-lymphoma drug therapy, including steroids,
             within 3 weeks of initiation of the study or use of any experimental non-drug therapy
             (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the
             study drug treatment.

          4. Known hypersensitivity to thalidomide or rituximab; including the development of
             erythema nodosum if characterized by a desquamating rash while taking thalidomide.

          5. Prior use of lenalidomide.

          6. Known HIV infection. Patients with active hepatitis B infection (not including
             patients with prior hepatitis B vaccination; not including patients with positive
             serum Hepatitis B antibody). Known hepatitis C infection is allowed as long as there
             is no active disease and is cleared by GI consultation.

          7. All patients with history of central nervous system lymphoma.

          8. Patients with peripheral blood involvement with white blood cell count (WBC) &gt; 20,000
             are EXCLUDED for the Phase I component of the study.

          9. Patients with &gt;/= Grade 3 neuropathy.

         10. Patients with active pulmonary embolism or deep vein thrombosis (30 days within
             diagnosis).

         11. Patients with severe bradycardia (heart rate &lt;40 bpm, hypotension, light-headedness,
             syncope).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 20, 2006</study_first_submitted>
  <study_first_submitted_qc>February 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2006</study_first_posted>
  <results_first_submitted>March 6, 2017</results_first_submitted>
  <results_first_submitted_qc>February 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2020</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>B-Cell Non-Hodgkin's Lymphoma</keyword>
  <keyword>Transformed Large Cell Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>MCL</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>CC-5013</keyword>
  <keyword>Revlimidâ¢</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: February 7, 2006 to February 21, 2011. All recruitment done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>There were 112 participants recruited for registration, 58 were screen failures prior to study inclusion</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I: Lenalidomide + Rituximab</title>
          <description>Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Phase II: Lenalidomide 20 mg + Rituximab</title>
          <description>Lenalidomide MTD Dose 20 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase I Dose Escalation Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cohort 1: 10 mg</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cohort 2: 15 mg</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cohort 3: 20 mg</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Cohort 4: 25 mg</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase II: 20 mg Lenalidomide</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase 1: Lenalidomide + Rituximab</title>
          <description>Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Phase II: Lenalidomide 20 mg + Rituximab</title>
          <description>Lenalidomide MTD Dose 20 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="56" upper_limit="84"/>
                    <measurement group_id="B2" value="64" lower_limit="46" upper_limit="85"/>
                    <measurement group_id="B3" value="66" lower_limit="46" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab</title>
        <description>MTD is defined as the highest dose level in which 1 or fewer participants experienced a dose limiting toxicity (DLT) in 6 participants treated. DLT is any grade III or IV toxicity during the first 28 days (first cycle) of therapy.</description>
        <time_frame>28 days of cycle 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Lenalidomide + Rituximab</title>
            <description>Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab</title>
          <description>MTD is defined as the highest dose level in which 1 or fewer participants experienced a dose limiting toxicity (DLT) in 6 participants treated. DLT is any grade III or IV toxicity during the first 28 days (first cycle) of therapy.</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response of Participants Treated at Lenalidomide 20 mg</title>
        <description>Response definitions for measurable disease from the International Workshop Standardized Response Criteria for non-Hodgkin's Lymphoma: Complete Response (CR): Disappearance of all clinical evidence of active tumor for a minimum of four weeks. Partial Response (PR): =/&gt;50% decrease in sum of products of all measured lesions persisting for &gt;four weeks. No lesion may increase in size &amp; no new lesion may appear. Minor Response (MR): &gt;25% but less than 50% response. Stable Disease: Steady state or response less than minor &amp; no progression for at least 8 weeks. There may be no appearance of significant new lesions. Progressive Disease: Unequivocal increase in size of any measurable lesion or appearance of significant new.</description>
        <time_frame>56 days, assessed after 2 cycles</time_frame>
        <population>Total analyzed includes Phase 2 participants (38) which includes six participants (6) that continued from Phase 1 who were treated with 20 mg Lenalidomide.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide 20 mg + Rituximab</title>
            <description>Lenalidomide MTD Dose 20 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Response of Participants Treated at Lenalidomide 20 mg</title>
          <description>Response definitions for measurable disease from the International Workshop Standardized Response Criteria for non-Hodgkin's Lymphoma: Complete Response (CR): Disappearance of all clinical evidence of active tumor for a minimum of four weeks. Partial Response (PR): =/&gt;50% decrease in sum of products of all measured lesions persisting for &gt;four weeks. No lesion may increase in size &amp; no new lesion may appear. Minor Response (MR): &gt;25% but less than 50% response. Stable Disease: Steady state or response less than minor &amp; no progression for at least 8 weeks. There may be no appearance of significant new lesions. Progressive Disease: Unequivocal increase in size of any measurable lesion or appearance of significant new.</description>
          <population>Total analyzed includes Phase 2 participants (38) which includes six participants (6) that continued from Phase 1 who were treated with 20 mg Lenalidomide.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate of Participants Treated With Lenalidomide 20 mg: Overall Response as % of Participants With Complete or Partial Response</title>
        <description>Objective response rate defined as percentage of participants with complete or partial response after 2 cycles of therapy maintained for one month. Objective response monitored using Simon's optimal 2-stage design.</description>
        <time_frame>56 days</time_frame>
        <population>Total analyzed includes Phase 2 participants (38) which includes six participants (6) that continued from Phase 1 who were treated with 20 mg Lenalidomide.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide + Rituximab</title>
            <description>Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate of Participants Treated With Lenalidomide 20 mg: Overall Response as % of Participants With Complete or Partial Response</title>
          <description>Objective response rate defined as percentage of participants with complete or partial response after 2 cycles of therapy maintained for one month. Objective response monitored using Simon's optimal 2-stage design.</description>
          <population>Total analyzed includes Phase 2 participants (38) which includes six participants (6) that continued from Phase 1 who were treated with 20 mg Lenalidomide.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of randomization until the date of death from any cause or study completion, whichever came first, assessed up to 10 years</time_frame>
      <desc>Phase 1 included a total 14 participants in the MTD determination while Phase 2 included 38 additional participants, reflected in the Adverse Reporting are 6 participants from Phase I dosed at 20 mg MTD to total 44 participants in that portion of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Lenalidomide + Rituximab</title>
          <description>Lenalidomide Starting Dose 10 mg, 15 mg, 20 mg or 25 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Phase II: Lenalidomide</title>
          <description>Lenalidomide MTD Dose 20 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 4 events</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>Grade 4 events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Unrelated, grade 4 non-neutropenic fever precursor</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Non-neutropenic infections</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post Radiation Treatment Complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leucopenia/leukocytopenia</sub_title>
                <description>White blood cell decreased</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <description>Grade 4 events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Snyocope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental Status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis or thromboembolism</sub_title>
                <description>Grade 4 events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" events="71" subjects_affected="44" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E2" events="53" subjects_affected="44" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" events="64" subjects_affected="44" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Red eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Oral cavity pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" events="58" subjects_affected="38" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Non-neutropenic infections</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Facial oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Oedema limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis or thromboembolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased liver function</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Raised blood urea nitrogen (BUN)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Raised Beta-2-Microglobulin (B2M)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Raised Lactate dehydrogenase (LDH or LD)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Limb pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Wang, Professor, Lymphoma/Myeloma</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-2860</phone>
      <email>miwang@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

